Revolutionizing Gene Editing: Advances in CRISPR/Cas Technology in Biomedical Applications

CRISPR/Cas technology, originally discovered as an adaptive immune system in prokaryotes to recognize and cut invading nucleic acids, has evolved into a powerful tool for gene editing in mammalian cells. The SpCas9 protein, derived from Streptococcus pyogenes, is the first Cas protein repurposed for genome editing, relying on synthetic guide RNA (sgRNA) to target specific nucleotide sequences within the genome.

The sgRNA comprises a scaffold sequence necessary for Cas9 binding and a customizable 20-nucleotide spacer that defines the genomic target. For effective double-strand breaks (DSB), the spacer sequence must meet two criteria: it should not complementarily pair with other genomic DNA and must be adjacent to a protospacer adjacent motif (PAM) sequence, which is essential for Cas9 binding.

The dual cutting activity of Cas9 relies on its two active sites, RuvC and HNH, allowing for precise DSB formation. Researchers have developed a variety of applications utilizing the CRISPR/Cas system, including:

1. Whole Genome Knockout Screening: By constructing a comprehensive sgRNA library and applying selective pressure, researchers can identify genes essential for cell survival under various conditions.

2. Gene Activation and Repression: Utilizing dCas9, which lacks nuclease activity, researchers can regulate gene expression by fusing dCas9 with transcriptional activators or repressors, enabling detailed exploration of gene functions.

3. Epigenetic Editing: dCas9 can be engineered to modify DNA or histones, allowing for targeted epigenetic alterations that can upregulate or silence gene expression.

4. Chromatin Imaging: By fusing dCas9 with fluorescent proteins, scientists can visualize specific genomic locations in live cells, enhancing our understanding of chromatin dynamics.

5. Identification of DNA/RNA Binding Proteins: Coupling CRISPR/Cas with proximity labeling technologies enables the identification of proteins interacting with specific genomic regions.

6. Molecular Evolution: The system can introduce mutations in targeted DNA sequences, facilitating the study of gene function under selective pressure.

7. Transposon-Mediated Insertion: By combining Cas proteins with transposases, researchers can achieve efficient integration of exogenous DNA into the genome.

8. Large Fragment Deletions: The CRISPR-Cas3 system allows for the removal of large DNA sequences, providing new therapeutic avenues for viral infections.

9. Memory Storage: Self-targeting gRNAs can create permanent mutations that serve as biological markers for specific events, paving the way for advanced tracking of cellular responses.

10. Viral Detection: CRISPR/Cas systems have been successfully applied in the rapid detection of viruses, including HIV and SARS-CoV-2, enhancing diagnostic capabilities.

11. Gene Therapy Innovations: The introduction of the first CRISPR/Cas9-based gene-editing drug, CASGEVY™, represents a significant milestone in treating sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). This drug, approved in multiple regions, highlights the potential for gene editing to transform therapeutic approaches.

As the field of gene editing continues to advance, the applications of CRISPR/Cas technology are expanding rapidly. With significant government investment in biotechnology and precision medicine, there are ongoing breakthroughs in gene editing therapies for various diseases, including genetic disorders, cancers, and Autoimmune Diseases.